

Preliminary Programme

Paris, France
5-7 November 2025

Wednesday, 5 November 2025

14:30-19:00 Lymphoma Working Party Scientific Business Meeting

Thursday, 6 November 2025

09:00-09:10 Welcome from the organizers

Ali Bazarbachi (LB)

09:10-11:00 Session I: Aggressive lymphomas – DLBCL
Chair: Bertram Glass (DE)

09:10-09:40 New classifiers: does it matter for treatment
09:40-09:50 Discussion

Fabrice Jardin (FR)

09:50-10:00 Clonal Evolution and Antigen Escape in Double-Hit DLBCL: An Aggressive Case with Early CAR-T Failure

Igor Kos (Germany)

10:00-10:10 From CAR-T Failure to Allogeneic Transplant: Glofitamab-Enabled Remission in Relapsed DLBCL

Taner Tan (Turkey)

10:10-10:40 Critical discussion of the presented cases and state-of-the-art

10:40-11:10 Is there still a role for autologous SCT in DLBCL Yes/No

10:40-10:50 Yes

Christian Gisselbrecht (FR)

10:50-11:00 No

Bertram Glass (DE)

11:00-11:10 Discussion

11:10-11:40 Coffee break

11:40-13:00 Session II: Mantle cell lymphoma
Chairs: Morgane Cheminant (FR) & Peter Dreger (DE)

11:40-12:00 New classifiers: does it matter for treatment

Morgane Cheminant (FR)

12:00-12:10 Junior presents a typical case of mantle cell lymphoma with several lines of treatment

12:10-12:30 Discussion of the non-cellular therapy strategies

Clemence Loiseau (FR)

12:30-12:50 Discussion of the cellular therapy options: transplant, CART-T and bi-specifics

Marco Ladetto (IT)

12:50-13:00 Discussion

Peter Dreger (DE)

13:00-14:00 Lunch break

14:00-15:20 Session III: Indolent B cell lymphoma
Chair: Nour Moukalled (LB) & Mahmoud Aljurf (SA)

14:00-14:20 New classifiers in follicular lymphoma: does it matter for treatment

Sandrine Roulland (FR)

14:20-14:30 From Indolent to Aggressive: Clinical Insights From A Case of Waldenström's Macroglobulinemia Transformed to High-Grade Lymphoma

Nour Moukalled (LB)

14:30-14:50 Discussion of the non-cellular therapy strategies including bispecifics

Chara Kyriakou (UK)

14:50-15:10 Discussion of the cellular therapy options: transplant, CART-T

Silvia Montoto (UK)

15:10-15:20 Discussion

15:30-16:50 Session IV: Peripheral T cell lymphoma
Chair: Gandhi Damaj (FR) & Olivier Tournilhac (FR)

15:30-15:50 New classifiers in TFH: does it matter for treatment

François Lemonnier (FR)

15:50-16:00 Refractory peripheral T cell lymphoma

Julieta Osorio Zuluaga (AE)

16:00-16:20 Standard treatment of the T-cell lymphoma with emphasis on allogeneic and autologous Transplantation + Q&A

Norbert Schmitz (DE)

16:20-16:40 The pipeline of T cell engaging therapy for T cell lymphoma: where do we stand? + Q&A

Pier Luigi Zinzani (IT)

16:40-16:50 Discussion

Thursday, 6 November 2025 – continued

Preliminary Programme

Paris, France
5-7 November 2025

17:00-17:30 Coffee break

17:30-18:10 Session V: Cutaneous T cell lymphoma
Chair: Alberto Mussetti (ES) & Eva Domingo (ES)

17:30-18:00 CTCL: State-of-the-art treatment and role of cellular therapy
18:00-18:10 Discussion

Eva Domingo (ES)

Friday, 7 November 2025

09:00-11:00 Session VI: Hodgkin lymphoma first line
Chair: Anna Sureda (ES) & Alina Tanase (RO)

09:00-09:20 New classifiers in classical HL: does it matter for treatment
09:20-09:30 Low-dose nivolumab combined with AVD chemotherapy in newly diagnosed advanced stage classic Hodgkin lymphoma
09:30-09:50 State-of-the-art treatment of NLPHL and role of cellular therapy
09:50-10:20 Choices and options in the first line
10:20-10:30 Discussion

Mobil Akhmedov (RU)
Dennis Eichenauer (DE)
Anna Sureda (ES)

10:30-11:00 Coffee break

11:00-12:30 Session VII: Hodgkin lymphoma in relapse and difficult to treat cases
Chair: Ali Bazarbachi (LB) & Luca Castagna (IT)

11:00-11:10 Non-Myeloablative Allo-HSCT Using TLI After Failed Autologous Stem Cell Mobilization in Hodgkin Lymphoma
11:10-11:40 Strategies at relapse
11:40-11:50 Refractory Hodgkin Lymphoma with complex post-allo-HCT course and nivolumab-associated complications
11:50-12:05 Lung Cancer Screening in Hodgkin Lymphoma
12:05-12:20 Survivors - a UK national initiative
12:20-12:30 Discussion

Anisiia Luchkiv (UA)
Ali Bazarbachi (LB)
Ludmila Federova (RU)
Prof Kim Linton (UK)

12:20-13:20 Lunch break

13:20-14:35 Session VIII: Supportive care in cellular therapy
Chairs: Anna Ossami Saidy (DE) & Rémy Duléry (US)

13:20-13:30 Severe Neurotoxicity and Spinal Myelopathy Following CD19 CAR-T Therapy in a Patient with Refractory DLBCL: A Case of Complex ICANS and Multidisciplinary Recovery
13:30-13:50 Management of cytopenia after CART
13:50-14:10 Neurological Complications after CART
14:10-14:30 From CRS to HLH following CART
14:30-14:35 Discussion

Amjad Hmaid (UK)
Martina Pennisi (IT)
Roser Velasco (ES)
Matteo Doglio (IT)

14:45-16:00 Session IX: Innovation in allotransplant
Chair: Yasmina Serroukh (NL)

14:45-15:05 Invariant NKT cells and risk of GVHD
15:05-15:30 Artificial intelligence and multi-omics in allotransplant
15:30-15:50 Methodology and bias in registry studies
15:50-16:00 Discussion

Jacques-E. Galimard (FR)

16:00-16:10 Closing remarks